Introduction: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described.

Methods: Data were pooled from four phase 3 studies. To be included in the head and neck analysis, patients were required to have Baseline head and neck Psoriasis Severity Area Index (PASI) scores &ge;12 and psoriasis covering &ge;10% of the head and neck. Secukinumab (300 or 150&nbsp;mg) was administered at Baseline, Weeks 1, 2 and 3, and then every 4&nbsp;weeks from Week 4 to 48.

Results: Secukinumab demonstrated high efficacy on the head and neck and the whole body. At Week 52, head and neck PASI 90/100 subscore responses were achieved by 76.0%/68.7% of patients receiving secukinumab 300&nbsp;mg, respectively, and by 61.4%/53.1% of patients receiving secukinumab 150&nbsp;mg, respectively. At Week 52, whole body composite PASI 90/100 responses were achieved by 68.1%/40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6%/24.3% of patients receiving secukinumab 150&nbsp;mg, respectively. Secukinumab also improved Dermatology Life Quality Index scores.

Conclusion: Secukinumab provided robust and sustained efficacy for head and neck, and whole body psoriasis, over 52&nbsp;weeks, with a favorable safety profile.

Mentions:
Pooled efficacy responses through Week 52 from these four phase 3 trials are presented in Fig. 3. In the overall pooled study population, secukinumab provided rapid skin clearance with responses being observed as early as Week 1. Initial responses were maintained to Week 52 and the greatest benefit was observed with secukinumab 300 mg. At Week 52, PASI 90 and PASI 100 were achieved by 68.1% and 40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6% and 24.3% of patients receiving secukinumab 150 mg, respectively.Fig. 3

Mentions:
Pooled efficacy responses through Week 52 from these four phase 3 trials are presented in Fig. 3. In the overall pooled study population, secukinumab provided rapid skin clearance with responses being observed as early as Week 1. Initial responses were maintained to Week 52 and the greatest benefit was observed with secukinumab 300 mg. At Week 52, PASI 90 and PASI 100 were achieved by 68.1% and 40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6% and 24.3% of patients receiving secukinumab 150 mg, respectively.Fig. 3

Introduction: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described.

Methods: Data were pooled from four phase 3 studies. To be included in the head and neck analysis, patients were required to have Baseline head and neck Psoriasis Severity Area Index (PASI) scores &ge;12 and psoriasis covering &ge;10% of the head and neck. Secukinumab (300 or 150&nbsp;mg) was administered at Baseline, Weeks 1, 2 and 3, and then every 4&nbsp;weeks from Week 4 to 48.

Results: Secukinumab demonstrated high efficacy on the head and neck and the whole body. At Week 52, head and neck PASI 90/100 subscore responses were achieved by 76.0%/68.7% of patients receiving secukinumab 300&nbsp;mg, respectively, and by 61.4%/53.1% of patients receiving secukinumab 150&nbsp;mg, respectively. At Week 52, whole body composite PASI 90/100 responses were achieved by 68.1%/40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6%/24.3% of patients receiving secukinumab 150&nbsp;mg, respectively. Secukinumab also improved Dermatology Life Quality Index scores.

Conclusion: Secukinumab provided robust and sustained efficacy for head and neck, and whole body psoriasis, over 52&nbsp;weeks, with a favorable safety profile.